[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intracranial-arterial-stenosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intracranial-arterial-stenosis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100652127","photon-counting-ct-for-intracranial-stent-assessment-100652127",false,"NCT07769814","Photon-counting CT for Intracranial Stent Assessment","Evaluation of Ultra-high Resolution Photon-counting CT Angiography for Intracranial Stent Assessment: A Prospective Diagnostic Study With Digital Subtraction Angiography as Reference Standard","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Patients with previously implanted intracranial arterial stents;\n3. Undergoing follow-up CTA examination;\n4. Available imaging data for analysis.\n\nExclusion Criteria:\n\n1. Severe motion artifacts;\n2. Poor contrast enhancement;\n3. Incomplete clinical or imaging data.","ALL","5 Years","90 Years",{"count":20,"type":21},200,"ESTIMATED","4 Years","OBSERVATIONAL","Intracranial atherosclerotic disease is an important cause of ischemic stroke, and intracranial stent implantation is increasingly used for patients with severe stenotic lesions. Evaluation of stent patency and detection of in-stent restenosis are essential during follow-up. Digital subtraction angiography (DSA) remains the reference standard for intracranial stent assessment; however, it is an invasive procedure associated with potential complications and radiation exposure. Conventional CT angiography may be limited by stent-related artifacts, including blooming artifact and beam-hardening effects, which can impair accurate evaluation of the stent lumen.",[26,27,28,29],"Intracranial Atherosclerotic Disease (ICAD)","Intracranial Arterial Stenosis","Stent Restenosis","Ischemic Stroke",[31,32,33,34,35],"Photon-counting CT","Ultra-high-resolution CT","In-stent restenosis","Intracranial stent","CT angiography","RECRUITING","2026-08-12",{"date":39,"type":40},"2026-08-18","ACTUAL",{"date":42,"type":40},"2026-01-07",{"date":44,"type":21},"2029-01-07",{"name":46,"class":47},"Xin Lou","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":48},"100620071","rapamycin-eluting-vertebral-stents-in-the-real-world-treatment-of-symptomatic-intracranial-atherosclerotic-stenosis-100620071","NCT07352852","Rapamycin-Eluting Vertebral Stents In The Real-World Treatment of Symptomatic Intracranial Atherosclerotic Stenosis","Rapamycin-eluting Vertebral Stents in the Real-world Treatment of Symptomatic Intracranial Atherosclerotic Stenosis","BRIDGE-INTRA","Inclusion Criteria:\n\n* Age ≥18 and ≤80 years;\n* Symptomatic intracranial atherosclerotic stenosis patients with ineffective medical treatment;\n* Digital subtraction angiography (DSA) shows target lesion stenosis ≥70%;\n* Suitable for implantation of rapamycin-targeted drug-eluting stents;\n* The patient and\u002For their authorized representative can understand the study purpose, agree to participate, and sign the informed consent form.\n\nExclusion Criteria:\n\n* Modified Rankin Scale (mRS) score ≥3;\n* Ischemic stroke within the past 2 weeks;\n* Presence of more than 2 intracranial atherosclerotic stenosis lesions requiring interventional treatment;\n* Severe contraindications to heparin, aspirin, ticagrelor, clopidogrel, or other antiplatelet drugs, and inability to tolerate anticoagulant\u002Fantiplatelet therapy;\n* Severe dysfunction of major organs (e.g., severe hepatic insufficiency, renal insufficiency, heart failure);\n* Severe allergies to contrast agents, rapamycin and its derivatives, cobalt-based alloys, or polylactic acid;\n* Pregnant or lactating women;\n* Participation in other drug or device studies without reaching the endpoint;\n* Life expectancy less than 12 months;\n* Lesions or vascular access deemed unsuitable for rapamycin drug-eluting stent implantation by the operator.","18 Years","80 Years",{"count":60,"type":21},300,"This clinical trial is a prospective, multicenter, single-arm study. About 300 subjects undergoing rapamycin-eluting stent implantation will be enrolled based on the inclusion and exclusion criteria. The primary endpoint is the rate of any stroke or death within 1 month. Secondary efficacy endpoints include immediate stent implantation success. Safety endpoints cover the incidence of stroke or neurological death, target-vessel-related stroke or death, all-cause mortality, and mRS scores at 12-month follow-ups. Subjects will be clinically followed up before surgery, device implantation, discharge, and at 1, 6, and 12 months post-surgery. An imaging subgroup of at least 80 subjects who agree to DSA follow-up at 12 months will assess in-stent restenosis (\\>50%).",[27,63],"Brain Diseases","2026-01-13",{"date":66,"type":40},"2026-01-20",{"date":68,"type":40},"2025-05-14",{"date":70,"type":21},"2028-12-31",{"name":72,"class":47},"The Affiliated Hospital of Qingdao University"]